Surgical Safety Checklist Linked to Drop in 90-Day Mortality

This article originally appeared here.
Share this content:
Surgical Safety Checklist Linked to Drop in 90-Day Mortality
Surgical Safety Checklist Linked to Drop in 90-Day Mortality

WEDNESDAY, Feb. 3, 2016 (HealthDay News) -- Implementation of a surgical safety checklist (SSC) correlated with a reduction in 90-day, but not 30-day, mortality among patients undergoing surgery, according to a study published online Feb. 3 in JAMA Surgery.

Matthias Bock, M.D., from the Bolzano Central Hospital in Italy, and colleagues examined the correlation between SSC implementation and mortality rates. They retrospectively examined the outcomes of surgical procedures performed during the six months before (Jan. 1 to June 30, 2010; 5,444 patients) and after (Jan. 1 to June 30, 2013; 5,297 patients) SSC implementation.

The researchers found that 90-day mortality was 2.4 and 2.2 percent before and after implementation, respectively (adjusted odds ratio [aOR], 0.73; 95 percent confidence interval [CI], 0.56 to 0.96; P = 0.02). Thirty-day all-cause mortality was 1.36 and 1.32 percent, respectively, before and after SSC implementation (aOR, 0.79; 95 percent CI, 0.56 to 1.11; P = 0.17). Thirty-day readmission occurred in 14.6 and 14.5 percent of the preimplementation and postimplementation groups, respectively (aOR, 0.90; 95 percent CI, 0.81 to 1.01; P = 0.79). The adjusted length of stay was significantly higher preimplementation versus postimplementation (10.4 versus 9.6 days; P < 0.001).

"The data cannot prove causality owing to the study design," the authors write. "The implementation of SSCs was associated with a 27 percent reduction of the adjusted risk for all-cause death within 90 days but not within 30 days."

The study was funded by the Public Health Care Company of South Tyrol.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »